Charles River Laboratories Intl. (CRL) Hits New 12-Month High at $139.72

Charles River Laboratories Intl. Inc (NYSE:CRL) reached a new 52-week high during trading on Monday . The stock traded as high as $139.72 and last traded at $138.57, with a volume of 6198 shares traded. The stock had previously closed at $134.85.

Several equities research analysts have recently commented on the stock. Morgan Stanley set a $136.00 target price on shares of Charles River Laboratories Intl. and gave the stock a “hold” rating in a research report on Monday. Raymond James raised shares of Charles River Laboratories Intl. from a “market perform” rating to an “outperform” rating and set a $140.00 target price for the company in a research report on Thursday, August 23rd. Credit Suisse Group decreased their target price on shares of Charles River Laboratories Intl. from $129.00 to $121.00 and set a “neutral” rating for the company in a research report on Tuesday, August 21st. Barclays boosted their target price on shares of Charles River Laboratories Intl. from $110.00 to $120.00 and gave the stock an “equal weight” rating in a research report on Thursday, August 9th. Finally, Jefferies Financial Group boosted their target price on shares of Charles River Laboratories Intl. from $140.00 to $145.00 and gave the stock a “buy” rating in a research report on Thursday, August 9th. Eight research analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. Charles River Laboratories Intl. currently has an average rating of “Buy” and an average price target of $132.06.

The firm has a market capitalization of $6.49 billion, a price-to-earnings ratio of 26.04, a PEG ratio of 1.90 and a beta of 0.74. The company has a debt-to-equity ratio of 1.32, a quick ratio of 1.32 and a current ratio of 1.55.

Charles River Laboratories Intl. (NYSE:CRL) last released its quarterly earnings results on Wednesday, November 7th. The medical research company reported $1.53 earnings per share for the quarter, topping the consensus estimate of $1.38 by $0.15. Charles River Laboratories Intl. had a net margin of 6.39% and a return on equity of 25.08%. The business had revenue of $585.30 million for the quarter, compared to analysts’ expectations of $567.58 million. During the same period in the previous year, the company earned $1.30 earnings per share. The firm’s revenue for the quarter was up 26.1% compared to the same quarter last year. Analysts forecast that Charles River Laboratories Intl. Inc will post 5.92 EPS for the current fiscal year.

In other Charles River Laboratories Intl. news, insider David Ross Smith sold 1,866 shares of the business’s stock in a transaction dated Monday, November 12th. The shares were sold at an average price of $134.49, for a total value of $250,958.34. Following the transaction, the insider now directly owns 12,341 shares in the company, valued at $1,659,741.09. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Deborah Turner Kochevar sold 4,066 shares of the business’s stock in a transaction dated Tuesday, September 4th. The shares were sold at an average price of $123.66, for a total transaction of $502,801.56. Following the completion of the transaction, the director now owns 10,190 shares in the company, valued at $1,260,095.40. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 29,288 shares of company stock worth $3,930,176. 2.10% of the stock is owned by corporate insiders.

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. NumerixS Investment Technologies Inc purchased a new position in Charles River Laboratories Intl. in the second quarter valued at about $122,000. Brown Brothers Harriman & Co. purchased a new position in Charles River Laboratories Intl. in the third quarter valued at about $202,000. CIBC Asset Management Inc purchased a new stake in shares of Charles River Laboratories Intl. during the 3rd quarter valued at approximately $226,000. Clinton Group Inc. purchased a new stake in shares of Charles River Laboratories Intl. during the 3rd quarter valued at approximately $241,000. Finally, Wsfs Capital Management LLC purchased a new stake in shares of Charles River Laboratories Intl. during the 2nd quarter valued at approximately $203,000. Hedge funds and other institutional investors own 96.20% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This piece of content was first reported by Community Financial News and is the sole property of of Community Financial News. If you are viewing this piece of content on another domain, it was illegally stolen and reposted in violation of United States and international copyright & trademark laws. The legal version of this piece of content can be read at https://www.com-unik.info/2018/12/03/charles-river-laboratories-intl-crl-hits-new-12-month-high-at-139-72.html.

Charles River Laboratories Intl. Company Profile (NYSE:CRL)

Charles River Laboratories International, Inc, an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services worldwide. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing).

Featured Article: Outstanding Shares, Buying and Selling Stocks

Receive News & Ratings for Charles River Laboratories Intl. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories Intl. and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit